Monthly Prescribing Reference

Livtencity Approved for Post-Transplant Cytomegalovirus Infection

Livtencity is an orally bioavailable anti-CMV compound that targets and inhibits the UL97 protein kinase and its natural substrates. The Food and Drug Administration (FDA) has approved Livtencity ...
Healio

FDA approves Livtencity as first treatment for cytomegalovirus infection after transplant

Please provide your email address to receive an email when new articles are posted on . Takeda Pharmaceuticals Company Limited announced FDA approval of Livtencity as the first treatment for patients ...
Nasdaq

Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies

- LIVTENCITY Is the First and Only Inhibitor of CMV-specific UL97 Protein Kinase Approved in China for the Treatment of Adults With Post-transplant CMV Infection/Disease Refractory* to Conventional ...
MedscapeOpinion

CMV: The Most Important Virus No One Talks About

Although it is the leading infectious cause of birth defects, patients and some doctors know little about cytomegalovirus.
Nasdaq

China Approves Takeda's Post-transplant Cytomegalovirus Treatment

(RTTNews) - Takeda (TAK) said that Livtencity (maribavir) has been approved by the National Medical Products Administration or NMPA of China for the treatment of adult patients with post-hematopoietic ...
Business Wire

Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior ...

− If Approved, Maribavir Would be the First and Only Inhibitor of CMV-specific UL97 Protein Kinase in the EU for Treatment of Adults with Post-transplant CMV Refractory (With or Without Resistance) to ...
Monthly Prescribing Reference

FDA Panel Votes on Maribavir for Post-Transplant CMV Infection

Credit: Getty Images. Maribavir is an orally bioavailable anti-CMV compound that targets and inhibits the UL97 protein kinase and its natural substrates. Maribavir is an orally bioavailable anti-CMV ...
Seeking Alpha

Chinese regulators approve Takeda's post-transplant CMV treatment

Takeda (NYSE:TAK) said Chinese regulators have approved its drug Livtencity for the treatment of adults with post-transplant CMV disease. China’s National Medical Products Administration approved the ...
Business Wire

FDA Advisory Committee Recommends Use of Investigational Drug Maribavir (TAK-620) to Treat Post-Transplant Recipients with Cytomegalovirus (CMV) Infection and Disease ...

− If approved by the FDA, maribavir will be the first and only treatment indicated for adults in this patient population − CMV is one of the most common infections experienced by transplant recipients ...
Newsweek

What Is Cytomegalovirus? Symptoms, Infection and Treatment Explained

The U.S. Centers for Disease Control and Prevention (CDC) has advised people to be wary of cytomegalovirus (CMV) during the holiday season. CMV is a common virus for people of all ages that is usually ...
Kashmir Reader

Silent Threat To Newborns: The Need For Greater Awareness And Action Against Congenital CMV Infection

With no vaccine available, early detection, hygiene practices, and public education are vital to prevent long-term disabilities caused by Human Cytomegalovirus in Kashmir’s children Dr Umer Majeed ...